Innoviva, Inc. - Jun 11, 2021 Form 4 Insider Report for Entasis Therapeutics Holdings Inc. (ETTX)

Role: 10%+ Owner
Signature: INNOVIVA, INC. By: /s/ Pavel Raifeld, Chief Executive Officer
Stock symbol: ETTX
Transactions as of: Jun 11, 2021
Transactions value $: $25,075,900
Form type: 4
Date filed: 6/11/2021, 05:39 PM
Previous filing: May 20, 2021
Next filing: Nov 1, 2021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ETTX	Common Stock	Purchase	$12.5M	+6.27M	+168.02%	$2.00	10M	Jun 11, 2021	See Footnote	F1
holding	ETTX	Common Stock						18.7M	Jun 11, 2021	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ETTX	Warrants to Purchase Common Stock	Purchase	$12.5M	+6.27M	+168.02%	$2.00	10M	Jun 11, 2021	Common Stock	6.27M	$2.00	See footnote	F1
holding	ETTX	Warrants to Purchase Common Stock						18.7M	Jun 11, 2021	Common Stock	18.7M		Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	As reflected in the Amendment No. 5 to Schedule 13D filed by Innoviva, Inc. ("INVA") and Innoviva Strategic Opportunities LLC, a wholly owned subsidiary of INVA ("ISO" and together with INVA, the "Reporting Persons") with the U.S. Securities and Exchange Commission on June 11, 2021 (the "Schedule 13D/A"), in connection the closing that occurred on June 11, 2021 pursuant to a securities purchase agreement, dated as of May 3, 2021 (the "Purchase Agreement" and, such closing, the "Closing"), by and between Entasis Therapeutics Holdings Inc. (the "Issuer") and ISO, ISO acquired 6,268,975 shares of common stock of the Issuer ("Shares") and warrants to purchase an additional 6,268,975 Shares ("Warrants" and together with the Shares, the "Security") for an aggregate price of $2.00 per Security as set forth in this Form 4. ISO previously acquired 3,731,025 shares of common stock of the issuer and warrants to purchase an aggregate 3,731,025 shares of common stock of the Issuer on May 3, 2021.
F2	(2) INVA acquired an aggregate of 18,672,897 shares of common stock of the issuer and warrants to purchase an aggregate 18,672,897 shares of common stock of the Issuer in transactions on April 22, 2020, June 11, 2020 and September 1, 2020.

Content

As reflected in the Amendment No. 5 to Schedule 13D filed by Innoviva, Inc. ("INVA") and Innoviva Strategic Opportunities LLC, a wholly owned subsidiary of INVA ("ISO" and together with INVA, the "Reporting Persons") with the U.S. Securities and Exchange Commission on June 11, 2021 (the "Schedule 13D/A"), in connection the closing that occurred on June 11, 2021 pursuant to a securities purchase agreement, dated as of May 3, 2021 (the "Purchase Agreement" and, such closing, the "Closing"), by and between Entasis Therapeutics Holdings Inc. (the "Issuer") and ISO, ISO acquired 6,268,975 shares of common stock of the Issuer ("Shares") and warrants to purchase an additional 6,268,975 Shares ("Warrants" and together with the Shares, the "Security") for an aggregate price of $2.00 per Security as set forth in this Form 4. ISO previously acquired 3,731,025 shares of common stock of the issuer and warrants to purchase an aggregate 3,731,025 shares of common stock of the Issuer on May 3, 2021.

(2) INVA acquired an aggregate of 18,672,897 shares of common stock of the issuer and warrants to purchase an aggregate 18,672,897 shares of common stock of the Issuer in transactions on April 22, 2020, June 11, 2020 and September 1, 2020.